metabolic research comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
==== Microwaves ==== A microwave oven, invented in 1950 by U.S. researcher Percy Spencer (1894-1970), is used to quickly heat food using microwave radiation at a frequency of 2.45 gigahertz. In an intact microwave oven, leakage radiation is relatively low due to the shielding of the cooking chamber. An "emission limit of five milliwatts per square centimeter (equivalent to 50 watts per square meter) at a distance of five centimeters from the surface of the appliance" (radiation density or power flux density) is specified. Children should not stand directly in front of or next to the appliance while food is being prepared. In addition, the Federal Office for Radiation Protection lists pregnant women as particularly at risk. In microwave therapy, electromagnetic waves are generated for heat treatment. The penetration depth and energy distribution vary depending on the frequency of application (short waves, ultra short waves, microwaves). To achieve greater penetration, pulsed microwaves are used, each of which delivers high energy to the tissue. A pulse pause ensures that no burns occur. Metal implants and pacemakers are contraindications.
Standard peptides synthesized from amino acids labeled with stable isotope atoms serve as internal standards for serial dilutions of a sample. These allow for later absolute quantification of proteins and post-translational modifications by mass spectrometry. This technique has been adapted to absolute quantification of proteases, deciphering both activity states and total amounts in biological samples. This is thanks to trypsin treatment for mass spectrometry generating peptides specific to inactive zymogen precursors, active proteases, or common to both forms. PSPs is one form of standard peptide for absolute quantification and Standard of the Expressed Protease (STEP) is the other. The major difference between the two is PSP sequences are designed to mimic tryptic peptides that contain sequences spanning the zymogen's pro-domain and the protease's final form, whereas STEP sequences match tryptic peptide sequences found in both forms of the protease. This capitalizes on protease activation, where the zymogen's pro-domain is cleaved off and the final form lacks that domain. Experiments using iTRAQ labeling and LC-MS/MS with STEP and PSP peptide internal standards have successfully quantified total and active protease levels in biological samples. One major drawback for this approach is the inability to account for inhibitor bound enzymes. It is also difficult to ensure standard peptides can be generated for this method for each and every protease for study.
Elagolix is taken by the oral route of administration, in contrast to other GnRH modulators. The oral bioavailability of elagolix in humans is not described in the Food and Drug Administration (FDA) label for the medication, but in animal research elagolix showed a low oral bioavailability of 5.8% in rats and 11% in monkeys. Following administration, elagolix is rapidly absorbed, with peak concentrations occurring after 0.5 to 1.5 hours. The drug accumulation ratio of elagolix at 150 mg once per day is 0.98 and at 200 mg twice per day is 0.89, indicating that it is not accumulated in the body with continuous administration. At steady state, peak levels of elagolix at 150 mg once per day are 574 ng/mL and at 200 mg twice per day are 774 ng/mL while area-under-the-curve levels of elagolix at 150 mg once per day are 1,292 ng•hour/mL and at 200 mg twice per day are 1,725 ng•hour/mL. A toxicology study found that levels of elagolix in women after a single dose of 1,200 mg were 17 times higher than in women taking 200 mg twice daily. Taking elagolix with a high-fat meal has been found to decrease its peak levels by 36% and its area-under-the-curve levels by 24%. In terms of distribution, the plasma protein binding of elagolix is 80% and its blood-to-plasma ratio is 0.6. The volume of distribution at steady state is 1,674 L at 150 mg once per day and 881 L at 200 mg twice per day. Elagolix is metabolized in the liver, with the major pathway being by CYP3A and minor pathways including by CYP2D6, CYP2C8, and UDP-glucuronosyltransferases.
==== Genicular artery embolization ==== Genicular artery embolization (GAE) is a minimally invasive image-guide procedure performed by interventional radiologists which involves blocks the abnormal vessels to reduce inflammation, ultimately reducing knee pain. By 12 months post-procedure, 78% and 92% of patients meet the clinical threshold for significant pain reduction by visual analog scale and total WOMAC score, respectively.
=== Extracellular actions of NAD+ === In recent years, NAD+ has also been recognized as an extracellular signaling molecule involved in cell-to-cell communication. NAD+ is released from neurons in blood vessels, urinary bladder, large intestine, from neurosecretory cells, and from brain synaptosomes, and is proposed to be a novel neurotransmitter that transmits information from nerves to effector cells in smooth muscle organs. In plants, the extracellular nicotinamide adenine dinucleotide induces resistance to pathogen infection and the first extracellular NAD receptor has been identified. Further studies are needed to determine the underlying mechanisms of its extracellular actions and their importance for human health and life processes in other organisms.
Sources: en.wikipedia.org
==== Sleep disorders ==== Modafinil, a eugeroic or wakefulness-promoting drug, is used for treating narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and sudden sleep attacks. Being a central nervous system (CNS) stimulant itself, modafinil has lower addictive potential than classical stimulants such as amphetamine, cocaine, or methylphenidate, but still produces psychoactive and subjective effects typical of classical stimulants. Narcolepsy causes a strong urge to sleep during the day and can include symptoms like cataplexy (sudden muscle weakness), sleep paralysis (inability to move or speak while falling asleep or waking up), and hallucinations. Narcolepsy is linked to a lack of the brain chemical hypocretin (orexin), primarily produced in the hypothalamus. Modafinil is not a cure for narcolepsy, but it can help manage the symptoms. While modafinil is used to treat excessive sleepiness, it may also help reduce the frequency and severity of cataplexy attacks in some people. Modafinil is approved for management of narcolepsy with or without cataplexy. However, it is not specifically approved for the treatment of cataplexy. Modafinil is also prescribed for shift work sleep disorder, a condition affecting people who work rotating or night shifts and experience excessive sleepiness during work hours and difficulty sleeping during the day. The recommended dose for this indication is 200 mg taken approximately one hour before the start of the work shift.
Nucleotide substitution (e.g., 76A>T) – The number is the position of the nucleotide from the 5' end; the first letter represents the wild-type nucleotide, and the second letter represents the nucleotide that replaced the wild type. In the given example, the adenine at the 76th position was replaced by a thymine. If it becomes necessary to differentiate between mutations in genomic DNA, mitochondrial DNA, and RNA, a simple convention is used. For example, if the 100th base of a nucleotide sequence mutated from G to C, then it would be written as g.100G>C if the mutation occurred in genomic DNA, m.100G>C if the mutation occurred in mitochondrial DNA, or r.100g>c if the mutation occurred in RNA. Note that, for mutations in RNA, the nucleotide code is written in lower case. Amino acid substitution (e.g., D111E) – The first letter is the one letter code of the wild-type amino acid, the number is the position of the amino acid from the N-terminus, and the second letter is the one letter code of the amino acid present in the mutation. Nonsense mutations are represented with an X for the second amino acid (e.g. D111X). Amino acid deletion (e.g., ΔF508) – The Greek letter Δ (delta) indicates a deletion. The letter refers to the amino acid present in the wild type and the number is the position from the N terminus of the amino acid were it to be present as in the wild type.
=== Pharmaceutical industry === In the pharmaceutical industry, ICP-MS is used for detecting inorganic impurities in pharmaceuticals and their ingredients. New and reduced maximum permitted exposure levels of heavy metals from dietary supplements, introduced in USP (United States Pharmacopeia) «〈232〉Elemental Impurities—Limits» and USP «〈233〉Elemental Impurities—Procedures», will increase the need for ICP-MS technology, where, previously, other analytic methods have been sufficient.
Absence of antibodies in patients with diagnoses of an autoimmune thyroid in their past would always be suspicious for development to SAT even in the presence of a normal TSH because there is no known recovery from autoimmunity. For clinical interpretation of laboratory results it is important to acknowledge that TSH is released in a pulsatile manner resulting in both circadian and ultradian rhythms of its serum concentrations.
Based in Matamoros, Tamaulipas, the Gulf Cartel (CDG) (Spanish: Cártel del Golfo) has long been one of Mexico's dominant criminal organizations. Its former arrangement with their armed wing, Los Zetas, collapsed in 2010, and both groups engaged in widespread violence across several border cities of Tamaulipas state, turning several border towns into "ghost towns". The CDG held off several Los Zetas incursions into its territory. However, by 2011, internal divisions led to intra-cartel battles in Matamoros and Reynosa. Infighting in the Gulf Cartel resulted in several arrests and deaths in Mexico and in the United States. The CDG has since broken apart, and it appears that one of its factions, known as Los Metros, has overpowered its rival, Los Rojos, and is now asserting its control over CDG operations. The Mexican federal government captured several leaders of the CDG during Joint Operation Nuevo León-Tamaulipas. Osiel Cárdenas Guillén, his brothers Antonio Cárdenas Guillén, Mario Cárdenas Guillén, and Jorge Eduardo Costilla Sánchez were captured and incarcerated during Felipe Calderón's administration.
Sources: en.wikipedia.org
=== Alkanes === For linear alkanes, molecular ion peaks are often observed. However, for long chain compounds, the intensity of the molecular ion peaks are often weak. Linear fragments often differ by 14 Da (CH2 = 14). For example, hexane fragmentation patterns. The m/z=57 butyl cation is the base peak, and other most abundant peaks in the spectrum are alkyl carbocations at m/z=15, 29, 43 Da.
== History == Modified atmosphere/modified humidity (MA/MH) packaging is a type of equilibrium modified atmosphere packaging (EMAP), which evolved due to the need for more control of humidity in the packaging. Most of the polymers that are commercially used in EMAP are polyolefin-based, characterized by low moisture vapor transmission rate (MVTR). Temperature fluctuations during the various links in the cold logistics chain are unavoidable and will result in condensation forming on the inner surface of the package. The accumulation of condensed water in packages with low MVTR is conducive for pathological and physiological disorders. Not only does excess moisture enhance fungal and bacterial decay and the formation of off odors, it also encourages leaf sprouting in topped root vegetables, regrowth of leaves and physiological disorders such as tissue discoloration and peel blemishes. Certain produce items are more sensitive to excess moisture than others.
== Precursors == Before the outbreak of World War II, Army commanders had recognized the inadequacy of heavy canned wet rations when employed for infantry marching on long patrols, especially in extreme environments such as mountain or jungle terrain. To this end, the Jungle ration was developed and briefly issued during early World War II. The Jungle ration was a dry, lightweight multi-component daily meal that could be stored in light waterproof bags, easily carried by a foot soldier, and which would not spoil when exposed to heat and humidity for an extended period of time. Importantly, the Jungle ration was specifically designed to provide an increased amount of dietary energy despite its lighter weight, ideal for a soldier operating in difficult jungle terrain on foot while carrying all of his equipment on his back. By all accounts the Jungle ration was successful; however, cost concerns led to its replacement, first by substitution of increasingly heavier and less expensive canned components, followed by complete discontinuance in 1943. After the war, U.S. Army logisticians again re-standardized field rations, eliminating all lightweight rations in favor of heavy canned wet rations such as the C-ration and the MCI. The overuse of heavy canned wet rations reached a ludicrous extreme during the early years of U.S. involvement in the Vietnam War, when American soldiers on extended infantry patrol were forced to stack their canned rations in socks to minimize weight and noise.
=== Modified Miller–Urey experiments === Much work has been done since the 1950s toward understanding how Miller–Urey chemistry behaves in various environmental settings. Different atmospheric compositions. In 1983, testing different atmospheric compositions, Miller and another researcher repeated experiments with varying proportions of H2, H2O, N2, CO2 or CH4, and sometimes NH3. They found that the presence or absence of NH3 in the mixture did not significantly impact amino acid yield, as NH3 was generated from N2 during the spark discharge. Additionally, CH4 proved to be one of the most important atmospheric ingredients for high yields, likely due to its role in HCN formation. Much lower yields were obtained with more oxidized carbon species in place of CH4, but similar yields could be reached with a high H2/CO2 ratio. Thus, Miller–Urey reactions work in atmospheres of other compositions as well, depending on the ratio of reducing and oxidizing gases. Role of nitrites and calcium carbonate. More recently, Jeffrey Bada and H. James Cleaves, graduate students of Miller, hypothesized that the production of nitrites, which destroy amino acids, in CO2 and N2-rich atmospheres may explain low amino acids yields. In a Miller–Urey setup with a less-reducing (CO2 + N2 + H2O) atmosphere, when they added calcium carbonate to buffer the aqueous solution and ascorbic acid to inhibit oxidation, yields of amino acids greatly increased, demonstrating that amino acids can still be formed in more neutral atmospheres under the right geochemical conditions.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.